Speed up! Nieuwe wetenschappelijke inzichten in de strijd tegen hiv/aids uit het NCHIV

he number of the second second

22 November 2016 Royal Tropical Institute, Amsterdam

NCHIV 2016


Session 1 Preventing HIV transmission

Chairs: Catherine Hankins & Marc van der Valk

22 November 2016 Royal Tropical Institute, Amsterdam



HIV Prevention in Europe Making it Happen Sheena McCormack Bacterial STIs in MSM, 2005-14



HIV Prevention in Europe - Making it Happen

Sheena McCormack

So make it happen

- Make the easy changes
 - use champions and social media to promote testing and raise awareness of PrEP
 - shorten the time to treatment
 - reward staff attitudes that reduce stigma
- Partner with community to
 - agitate for PrEP and more testing
 - deliver PrEP safely

Informal PrEP use among MSM in Europe first results from the EU Flash PrEP survey



Medical Check-ups Kai J. Jonas Maastricht University

Prior (kidney/liver)	N (%)	
Yes	150 (48.1)	
No	162 (51.9)	

Creatine use and informal

PrEP use: 17.7%

During use	overall N (%)	Daily N (%)	Interm. N (%)
Once before start	27 (18.2)	16 (16.2)	9 (25)
Every three months	96 (64.9)	71 (71.7)	16 (44.4)
Irregularly	25 (16.9)	12 (12.1)	11 (30.6)

HIV testing	A lot lower than before N (%)	Lower than before N (%)	The same	Higher than before N (%)	A lot higher than before N (%)
Daily	2 (1.3)	4 (2.6)	69 (45.4)	51 (33.6)	26 (17.1)
Intermittent	2 (1.4)	3 (2.1)	90 (63.4)	39 (27.5)	8 (5.6)






Motivations for joining AMPrEP



Elske Hoornenborg GGD Amsterdam



NCHIV 2016

Session 2 Challenging issues in HIV care

Chairs: Eline op de Coul & Guido van den Berk

22 November 2016 Royal Tropical Institute, Amsterdam








Alexander Pastoors HVN




HCV treatment cascade of care






Immune activation by HIV-1 enhances sexual transmission of Hepatitis C virus by human primary Langerhans cells



Bernadien Nijmeijer AMC

Alarmingly high rate of primary HIV drug resistance in infants in Nigeria



NCHIV 2016

Session 3 Optimising the HIV care continuum

Chairs: Suzanne Geerlings & Maarten Schim van der Loeff

22 November 2016 Royal Tropical Institute, Amsterdam



Integrase inhibitor use is an independent risk factor for immune reconstitution inflammatory syndrome (IRIS) in HIV-1 late presenters in the Dutch ATHENA cohort



Cox regression analysis:


	IRIS French + clin. HR (95%CI), p-value	IRIS French HR (95%CI), p-value
Use of INI	2.69 (1.63-4.44), 0.0001	2.62 (1.35-5.10), 0.0045
Female gender	1.64 (0.97-2.78), 0.067	-
Diagnosed with CM	3.71 (1.55-8.88), 0.0033	11.6 (4.77-28.3), <0.0001
Diagnosed with MAC	2.46 (1.04-5.84), 0.041	-
Diagnosed with CMV	2.25 (1.06-4.79), 0.035	4.23 (1.84-9.74), 0.0007

No other investigated parameters were significant predictors of IRIS. No interactions between use of INI and any of the other parameters.

Ingeborg Wijting Erasmus MC



Undiagnosed HIV infections in Amsterdam



- 400 (95% CI, 260 660) people living with HIV were still undiagnosed by the end of 2015.
- Number undiagnosed consistent with earlier estimates (Op de Coul et al, PLoS One 2015).


HIV Transmissie Eliminatie AMsterdam HIV Transmission Elimination AMsterdam

Ard van Sighem SHM



Amsterdam HIV care continuum in 2015

Total population



HIV Transmissie Eliminatie AMsterdam HIV Transmission Elimination AMsterdam

ART Guidelines: Conclusions

 ART today is highly active, safe and tolerable, convenient, increasingly available, and prolongs healthy life.

- ART in 10 years will be:
 - Highly active, including against drug-resistant strains
 - Even more safe and tolerable (including long-term)
 - Even more convenient, including long-acting and implantable formulations
 - Even more widely available and affordable
 - Associated with a normal life expectancy for HIV-infected people (compared to the general population)

NCHIV 2016

Session 4 The road to cure

Chairs: Tokameh Mahmoudi & Daniel Kuritzkes

22 November 2016 Royal Tropical Institute, Amsterdam



Viable pathways towards a durable remission/cure: Gene therapy

Viable pathways towards a durable remission/cure: Early ART

Viable pathways towards a durable remission/cure: Shock and kill

Viable pathways towards a durable remission/cure: Immunotherapy


Combination strategies will likely be needed to achieve a durable remission

A number of viable combinations should be available for testing in a few years

Steven Deeks, San Francisco

gRNA-guided CRISPR/Cas9 nuclease





A bright future for Dutch HIV research

Elevator pitches by recipients of the Aids Fonds' high risk, high-gain grants

- A costimulatory power-boost for HIV-specific T-cells through GITR activation M. Fernanda Pascutti (Sanquin Research)
- Development of a natural drug "mimic" derived from dendritic cells that activate latent HIV-1 and potentially could cure infected patients Thijs van Montfort (AMC)
- Can the CRISPR-Cas9 system be used to cure HIV-1 infected cells? Atze Das (AMC)
- The FIND study: fine-needle biopsies to detect the hidden HIV reservoirs in hard-toreach tissue compartments of well-controlled and uncontrolled HIV-patients Annemarie Wensing (UMC Utrecht)
- New, less cumbersome screening method for anal (pre)cancer, based on DNA changes, in HIV+ men who have sex with men Olivier Richel (AMC)
- Peer empowered Volunteery Extended Network Testing for Ethnic Minority-MSM Eline op de Coul (RIVM)



For further information

Please visit our website (<u>www.hiv-monitoring.nl</u>) and read or download the new digital HIV Monitoring Report.

- Fully searchable PDF,
 with appendix figures and tables included
- All figures available separately as powerpoint file at <u>www.hiv-monitoring.nl</u>
- Summary and Recommendations on website & in print (see NCHIV bag)

